ALK and non-small cell lung carcinoma: Crizotinib is a kinase inhibitor indicated for the treatment of adult patients with metastatic NSCLC whose tumors are anaplastic lymphoma kinase (ALK) or ROS1-positive as detected by an FDA-approved test.